Escherichia coli Sequence Type 131 Is a Dominant, Antimicrobial-Resistant Clonal Group Associated with Healthcare and Elderly Hosts

被引:111
|
作者
Banerjee, Ritu [1 ]
Johnston, Brian [2 ,3 ]
Lohse, Christine [1 ,4 ]
Porter, Stephen B. [2 ,3 ]
Clabots, Connie [2 ,3 ]
Johnson, James R. [2 ,3 ]
机构
[1] Mayo Clin, Dept Pediat & Adolescent Med, Rochester, MN USA
[2] Vet Affairs Med Ctr, Minneapolis, MN USA
[3] Univ Minnesota, Minneapolis, MN USA
[4] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA
基金
美国国家卫生研究院;
关键词
M BETA-LACTAMASES; CTX-M; UNITED-STATES; E; COLI; ST131; COMMUNITY; KLEBSIELLA; EMERGENCE; IDENTIFICATION; INFECTIONS;
D O I
10.1086/669865
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
OBJECTIVE. To determine prevalence, predictors, and outcomes of infection due to Escherichia coli sequence type ST131. DESIGN. Retrospective cohort. SETTING. All healthcare settings in Olmsted County, Minnesota (eg, community hospital, tertiary care center, long-term care facilities, and ambulatory clinics). PATIENTS. Ambulatory and hospitalized children and adults with extraintestinal E. coli isolates. METHODS. We analyzed 299 consecutive, nonduplicate extraintestinal E. coli isolates submitted to Olmsted County laboratories in February and March 2011. ST131 was identified using single-nucleotide polymorphism polymerase chain reaction and further evaluated through pulsed-field gel electrophoresis. Associated clinical data were abstracted through medical record review. RESULTS. Most isolates were from urine specimens (90%), outpatients (68%), and community-associated infections (61%). ST131 accounted for 27% of isolates overall and for a larger proportion of those isolates resistant to fluoroquinolones (81%), trimethoprim-sulfamethoxazole (42%), gentamicin (79%), and ceftriaxone (50%). The prevalence of ST131 increased with age (accounting for 5% of isolates from those 11-20 years of age, 26% of isolates from those 51-60 years of age, and 50% of isolates from those 91-100 years of age). ST131 accounted for a greater proportion of healthcare-associated isolates (49%) than community-associated isolates (15%) and for fully 76% of E. coli isolates from long-term care facility (LTCF) residents. Multivariable predictors of ST131 carriage included older age, LTCF residence, previous urinary tract infection, high-complexity infection, and previous use of fluoroquinolones, macrolides, and extendedspectrum cephalosporins. With multivariable adjustment, ST131-associated infection outcomes included receipt of more than 1 antibiotic (odds ratio [OR], 2.54 [95% confidence interval (CI), 1.25-5.17]) and persistent or recurrent symptoms (OR, 2.53 [95% CI, 1.08-5.96]). Two globally predominant ST131 pulsotypes accounted for 45% of ST131 isolates. CONCLUSIONS. ST131 is a dominant, antimicrobial-resistant clonal group associated with healthcare settings, elderly hosts, and persistent or recurrent symptoms. Infect Control Hosp Epidemiol 2013;34(4):361-369
引用
收藏
页码:361 / 369
页数:9
相关论文
共 38 条
  • [21] Clonal diversity, virulence genes content and subclone status of Escherichia coli sequence type 131: comparative analysis of E. coli ST131 and non-ST131 isolates from Iran
    Hojabri, Zoya
    Darabi, Narges
    Arab, Maedeh
    Saffari, Fereshteh
    Pajand, Omid
    BMC MICROBIOLOGY, 2019, 19 (1)
  • [22] Success of Escherichia coli O25b:H4 Sequence Type 131 Clade C Associated with a Decrease in Virulence
    Duprilot, Marion
    Baron, Alexandra
    Blanquart, Francois
    Dion, Sara
    Pouget, Cassandra
    Letteron, Philippe
    Flament-Simon, Saskia-Camille
    Clermont, Olivier
    Denamur, Erick
    Nicolas-Chanoine, Marie-Helene
    INFECTION AND IMMUNITY, 2020, 88 (12)
  • [23] Escherichia coli Sequence Type ST131 as the Major Cause of Serious Multidrug-Resistant E. coli Infections in the United States
    Johnson, James R.
    Johnston, Brian
    Clabots, Connie
    Kuskowski, Michael A.
    Castanheira, Mariana
    CLINICAL INFECTIOUS DISEASES, 2010, 51 (03) : 286 - 294
  • [24] Clinical and Molecular Epidemiology of Escherichia coli Sequence Type 131 among Hospitalized Patients Colonized Intestinally with Fluoroquinolone-Resistant E-coli
    Han, Jennifer H.
    Johnston, Brian
    Nachamkin, Irving
    Tolomeo, Pam
    Bilker, Warren B.
    Mao, Xiangqun
    Clabots, Connie
    Lautenbach, Ebbing
    Johnson, James R.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (11) : 7003 - 7006
  • [25] Epidemiology and Antimicrobial Resistance Characteristics of the Sequence Type 131-&ITH30&IT Subclone Among Extraintestinal&IT Escherichia coli&IT Collected From US Children
    Miles-Jay, Arianna
    Weissman, Scott J.
    Adler, Amanda L.
    Tchesnokova, Veronika
    Sokurenko, Evgeni V.
    Baseman, Janet G.
    Zerr, Danielle M.
    CLINICAL INFECTIOUS DISEASES, 2018, 66 (03) : 411 - 419
  • [26] Susceptibility to Alternative Oral Antimicrobial Agents in Relation to Sequence Type ST131 Status and Coresistance Phenotype among Recent Escherichia coli Isolates from US Veterans
    Johnson, James R.
    Drawz, Sarah M.
    Porter, Stephen
    Kuskowski, Michael A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (10) : 4856 - 4860
  • [27] Fluoroquinolone-Resistant Sequence Type 131 Subgroups O25b and O16 Among Extraintestinal Escherichia coli Isolates from Community-Acquired Urinary Tract Infections
    Hefzy, Enas Mamdouh
    Hassuna, Noha Anwar
    MICROBIAL DRUG RESISTANCE, 2017, 23 (02) : 224 - 229
  • [28] Susceptibility to disinfectants in antimicrobial-resistant and -susceptible isolates of Escherichia coli, Enterococcus faecalis and Enterococcus faecium from poultry-ESBL/AmpC-phenotype of E. coli is not associated with resistance to a quaternary ammonium compound, DDAC
    Wieland, N.
    Boss, J.
    Lettmann, S.
    Fritz, B.
    Schwaiger, K.
    Bauer, J.
    Hoelzel, C. S.
    JOURNAL OF APPLIED MICROBIOLOGY, 2017, 122 (06) : 1508 - 1517
  • [29] Prominence of an O75 Clonal Group (Clonal Complex 14) among Non-ST131 Fluoroquinolone-Resistant Escherichia coli Causing Extraintestinal Infections in Humans and Dogs in Australia
    Platell, Joanne L.
    Trott, Darren J.
    Johnson, James R.
    Heisig, Peter
    Heisig, Anke
    Clabots, Connie R.
    Johnston, Brian
    Cobbold, Rowland N.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (07) : 3898 - 3904
  • [30] Intensity and Mechanisms of Fluoroquinolone Resistance within the H30 and H30Rx Subclones of Escherichia coli Sequence Type 131 Compared with Other Fluoroquinolone-Resistant E. coli
    Johnson, James R.
    Johnston, Brian
    Kuskowski, Michael A.
    Sokurenko, Evgeni V.
    Tchesnokova, Veronika
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (08) : 4471 - 4480